Notice: Undefined offset: 1 in /var/www/jopcr.com/article-detail-page.php on line 103
Antihyperglycemic Effect of Novel Pyridazinone Derivative on the Alloxan-Induced Diabetes Model in Rats
 
  • P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Antihyperglycemic Effect of Novel Pyridazinone Derivative on the Alloxan-Induced Diabetes Model in Rats
  • VIEWS 16
  • PDF 10

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v24.i3.97

Year: 2025, Volume: 24, Issue: 3, Pages: 179–184

Original Article

Antihyperglycemic Effect of Novel Pyridazinone Derivative on the Alloxan-Induced Diabetes Model in Rats

Reetesh Kumar Rai1, A Sudhindra Prathap2,∗, N D Jayanna3

1Associate Professor, Department of Pharmacology, MRA Medical College, Ambedkar Nagar, UP, India
2Assistant Professor, Department of Pharmacology, SDM college of medical sciences and hospital, Dharwad, Karnataka, India
3Department of Chemistry, K.L.E Society’s Shri Shivayogi Murughendra Swamiji Arts, Science and Commerce College, Athani, Karnataka, India

*Corresponding Author
Email: prathapsudhi@gmail.com

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Type 2 diabetes mellitus represents a significant and escalating global health concern. Projections estimate that the number of individuals living with diabetes will increase dramatically, rising from 425 million in 2017 to approximately 629 million by 2045. While available antidiabetic medications are effective, their use is frequently accompanied by adverse effects, including low blood sugar and digestive disturbances, underscoring the need for safer alternatives. Pyridazinones, a class of six-membered nitrogen-containing heterocycles with adjacent nitrogen atoms, have emerged as promising scaffolds in medicinal chemistry. Specifically, pyridazine-3-one, which features a carbonyl group at the third position, is recognized for its wide spectrum of biological activities. By introducing a benzoxazole ring onto the pyridazinone framework, researchers aim to enhance and explore novel antidiabetic properties in these derivatives. Thus, the novel compound 1-(5-chloro-1,3-benzoxazol-2-yl)-4-methyl-1,2-dihydropyridazine-3,6-dione has been synthesized and is proposed for evaluation as a potential antidiabetic agent.

Keywords: Diabetes mellitus, Pyridazinone, Benzoxazole

References

  3. George AM, Jacob AG, Fogelfeld L. Lean diabetes mellitus: An emerging entity in the era of obesity. World Journal of Diabetes. 2015;6(4):613–620. Available from: https://dx.doi.org/10.4239/wjd.v6.i4.613
  4. Karuranga S, Fernandes JDR, Huang Y, Malanda B. International Diabetes Federation. IDF Diabetes Atlas (8). (p. 150 pages) Brussels, Belgium. International Diabetes Federation. 2017.
  5. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal. 2013;34(31):2444–2452. Available from: https://dx.doi.org/10.1093/eurheartj/eht142
  6. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal. 2007;29(2):270–276. Available from: https://dx.doi.org/10.1093/eurheartj/ehm342
  7. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, Lusignan Sd. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2018;20(4):1040–1043. Available from: https://dx.doi.org/10.1111/dom.13160
  9. Tisler M, Stanovnlk B. Comprehensive Heterocyclic Chemistry. 1984. 3(1).
  11. Husain A, Ahmad A, Bhandari A, Ram V. Synthesis And Antitubercular Activity Of Pyridazinone Derivatives. Journal of Chilean Chemical Society. 2011;56(3):778–780. Available from: https://scielo.conicyt.cl/pdf/jcchems/v56n3/art13.pdf
  15. Costas T, Besada P, Piras A, Acevedo L, Yañez M, Orallo F, et al. New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities. Bioorganic & Medicinal Chemistry Letters. 2010;20(22):6624–6627. Available from: https://dx.doi.org/10.1016/j.bmcl.2010.09.031
  18. Seth S, Sharma A, Raj D. Pyridazinones: A Wonder Nucleus With Scaffold Of Pharmacological Activities. American Journal of Biological and Pharmaceutical Research. 2014;1(3):105–116. Available from: https://mcmed.us/dart/abstract/268/ajbpr
  19. Yaseen R, Pushpalatha H, Reddy GB, Ismael A, Ahmed A, Dheyaa A, et al. Design and synthesis of pyridazinone-substituted benzenesulphonylurea derivatives as anti-hyperglycaemic agents and inhibitors of aldose reductase – an enzyme embroiled in diabetic complications. Journal of Enzyme Inhibition and Medicinal Chemistry. 2016;31(6):1415–1427. Available from: https://dx.doi.org/10.3109/14756366.2016.1142986
  20. Elnima EI, Zubair MU, Al-Badr AA. Antibacterial and antifungal activities of benzimidazole and benzoxazole derivatives. Antimicrobial Agents and Chemotherapy. 1981;19(1):29–32. Available from: https://dx.doi.org/10.1128/aac.19.1.29
  21. Akbay A, Oren I, Temiz-Arpaci O, Aki-Sener E, Yalçin I. Synthesis and HIV-1 reverse transcriptase inhibitor activity of some 2,5,6-substituted benzoxazole, benzimidazole, benzothiazole and oxazolo(4,5-b)pyridine derivatives. Arzneimittelforschung Drug Research. 2003;53(4):266–271. Available from: https://doi.org/10.1055/s-0031-1297107
  22. Oksuzoglu E, Tekiner-Gulbas B, Alper S, Temiz-Arpaci O, Ertan T, Yildiz I, et al. Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2008;23(1):37–42. Available from: https://dx.doi.org/10.1080/14756360701342516
  23. Kumar D, Jacob MR, Reynolds MB, Kerwin SM. Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorganic & Medicinal Chemistry. 2002;10(12):3997–4004. Available from: https://dx.doi.org/10.1016/s0968-0896(02)00327-9
  24. Ashton WT, Sisco RM, Dong H, Lyons KA, He H, Doss GA, et al. Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole. Bioorganic & Medicinal Chemistry Letters. 2005;15(9):2253–2258. Available from: https://dx.doi.org/10.1016/j.bmcl.2005.03.012
  25. El-Mofty SK, Scrutton MC, Serroni A, Nicolini C, Farber JL. Early, reversible plasma membrane injury in galactosamine-induced liver cell death. American Journal of Pathology. 1975;79(3):579–596. Available from: https://pubmed.ncbi.nlm.nih.gov/1137005/
  26. Al-Shamaony L, Al-Khazraji SM, Twaij HAA. Hypoglycaemic effect of Artemisia herba alba. II. Effect of a valuable extract on some blood parameters in diabetic animals. Journal of Ethnopharmacology. 1994;43(3):167–171. Available from: https://dx.doi.org/10.1016/0378-8741(94)90038-8
  27. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clinical Chemistry. 1993;39(4):578–582. Available from: https://dx.doi.org/10.1093/clinchem/39.4.578
  28. Drabkin DL, JMA. Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. Journal of Biological Chemistry. 1932;98(2):719–733. Available from: https://doi.org/10.1016/S0021-9258(18)76122-X
  29. Nayak SS, Pattabiraman TN. A new colorimetric method for the estimation of glycosylated hemoglobin. Clinica Chimica Acta. 1981;109(3):267–274. Available from: https://dx.doi.org/10.1016/0009-8981(81)90312-0
  30. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl 2):S97–S107. Available from: https://doi.org/10.2337/diabetes.54.suppl_2.s97
  32. Colca JR, Kotagal N, Brooks CL, Lacy PE, Landt M, McDaniel ML. Alloxan inhibition of a Ca2+- and calmodulin-dependent protein kinase activity in pancreatic islets. Journal of Biological Chemistry. 1983;258(12):7260–7263. Available from: https://dx.doi.org/10.1016/s0021-9258(18)32168-9
  33. Alberti KGMM, Press CM. The biochemistry of the complication of diabetes mellitus. In: Keen H, Jarrett J., eds. Complications of Diabetes (2). (pp. 231-270) London. Edward Arnold Ltd.. 1982.
  34. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of Glucose Regulation and Hemoglobin A<sub>Ic</sub>in Diabetes Mellitus. New England Journal of Medicine. 1976;295(8):417–420. Available from: https://dx.doi.org/10.1056/nejm197608192950804
  35. Jackson RL, Hess RL, England JD. Hemoglobin a1c values in children with overt diabetes maintained in varying degrees of control. Diabetes Care. 1979;2(5):391–395. Available from: https://doi.org/10.2337/diacare.2.5.391
  36. Sheela CG, Augusti KT. Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn. Indian Journal of Experimental Biology (IJEB). 1992;30(6):523–526. Available from: https://pubmed.ncbi.nlm.nih.gov/1506036/

Copyright

© 2025 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 16 November 2025

Year: 2025, Volume: 24, Issue: 3


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.